By Chris Wack
Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.
The biopharmaceutical company had a quarterly loss of $25.4 million, or 4 cents a share, compared with a loss of $52 million, or 9 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $12 million, or 2 cents a share.
Revenue for the quarter was $47.5 million, compared with last year's $23,000 and the $61.8 million analysts were expecting.
Geron expects to reach profitability without additional financing if current internal sales and operating expenses expectations are met. The company launched Rytelo, a telomerase inhibitor, at the end of June.
Geron had $502.9 million in cash and cash equivalents at Dec. 31.
For fiscal 2025, the company is looking for total operating expenses to be $270 million to $285 million.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 26, 2025 13:11 ET (18:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.